Praxis Precision Medicines/$PRAX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Praxis Precision Medicines
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
Ticker
$PRAX
Sector
Primary listing
Employees
116
Headquarters
Website
PRAX Metrics
BasicAdvanced
$927M
-
-$12.33
2.63
-
Price and volume
Market cap
$927M
Beta
2.63
52-week high
$91.83
52-week low
$26.70
Average daily volume
427K
Financial strength
Current ratio
9.445
Quick ratio
6.198
Long term debt to equity
0.187
Total debt to equity
0.187
Profitability
EBITDA (TTM)
-271.354
Gross margin (TTM)
-2,758.74%
Net profit margin (TTM)
-3,232.61%
Operating margin (TTM)
-3,497.57%
Revenue per employee (TTM)
$70,000
Management effectiveness
Return on assets (TTM)
-37.98%
Return on equity (TTM)
-60.98%
Valuation
Price to revenue (TTM)
115.436
Price to book
2.29
Price to tangible book (TTM)
2.29
Price to free cash flow (TTM)
-4.684
Free cash flow yield (TTM)
-21.35%
Free cash flow per share (TTM)
-9.4
Growth
Revenue change (TTM)
338.45%
Earnings per share change (TTM)
26.82%
3-year earnings per share growth (CAGR)
-45.71%
What the Analysts think about PRAX
Analyst ratings (Buy, Hold, Sell) for Praxis Precision Medicines stock.
Bulls say / Bears say
As of June 30, 2025, Praxis held about $447 million in cash and marketable securities, enough to fund the company into 2028 and support its advanced clinical pipeline (GlobeNewswire)
Vormatrigine continues to offer a leading safety profile without a food effect and with improved dosing tolerance, distinguishing it within common epilepsy treatments (GlobeNewswire)
In July 2025, relutrigine received FDA Breakthrough Therapy Designation for seizures linked to SCN2A and SCN8A developmental and epileptic encephalopathies, potentially speeding up its approval process (GlobeNewswire)
An interim analysis of the Essential3 Phase 3 Study 1 for ulixacaltamide showed the trial was unlikely to meet its primary efficacy endpoint, creating uncertainty for a planned 2025 NDA filing (GlobeNewswire)
Cash and investments fell by $22.9 million between December 31, 2024, and June 30, 2025, mainly due to spending on operations, highlighting a notable cash burn for the quarter (GlobeNewswire)
Research and development expenses jumped 131% year-over-year to $63.0 million in Q2 2025, reflecting significant spending on late-stage projects and raising the risk of future shareholder dilution (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
PRAX Financial Performance
Revenues and expenses
PRAX Earnings Performance
Company profitability
PRAX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Praxis Precision Medicines stock?
Praxis Precision Medicines (PRAX) has a market cap of $927M as of September 18, 2025.
What is the P/E ratio for Praxis Precision Medicines stock?
The price to earnings (P/E) ratio for Praxis Precision Medicines (PRAX) stock is 0 as of September 18, 2025.
Does Praxis Precision Medicines stock pay dividends?
No, Praxis Precision Medicines (PRAX) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Praxis Precision Medicines dividend payment date?
Praxis Precision Medicines (PRAX) stock does not pay dividends to its shareholders.
What is the beta indicator for Praxis Precision Medicines?
Praxis Precision Medicines (PRAX) has a beta rating of 2.63. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.